Briacell Therapeutics shares fall 2.54% premarket after announcing share consolidation.

Briacell Therapeutics Corp. declined 2.54% in premarket trading. The company announced that it has been awarded a non-dilutive grant of $2,054,651 from the US National Cancer Institute (NCI) to advance Bria-PROS+, its next-generation personalized off-the-shelf immunotherapy for prostate cancer. This grant will be utilized to complete the manufacturing of Bria-PROS+ clinical supply and support the upcoming Phase 1/2a trial in patients with metastatic prostate cancer. The principal investigator for this trial is Dr. William Oh, MD, from Yale Cancer Center.